XML 20 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows Statement - USD ($)
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net income (loss) including noncontrolling interests in operating subsidiaries $ (43,922,000) $ (40,128,000)
Adjustments to reconcile net loss including noncontrolling interests in operating subsidiaries to net cash provided by operating activities:    
Depreciation and amortization 28,105,000 40,129,000
Non-cash stock compensation 5,754,000 8,588,000
Impairment of patent-related intangible assets 40,165,000 0
Other (81,000) (127,000)
Changes in assets and liabilities:    
Restricted cash (3,316,000) (10,721,000)
Accounts receivable (20,200,000) 7,411,000
Prepaid expenses and other assets 1,191,000 (569,000)
Accounts payable and accrued expenses 5,392,000 2,680,000
Royalties and contingent legal fees payable 10,131,000 (5,108,000)
Net cash provided by operating activities 23,219,000 2,155,000
Cash flows from investing activities:    
Investments in patents/ patent rights (1,000,000) (19,504,000)
Payments to Acquire Notes Receivable (8,280,000) 0
Payments for (Proceeds from) Investments (1,720,000) 0
Purchases of property and equipment (4,000) (8,000)
Purchase of available-for-sale investments (62,633,000) (23,296,000)
Maturities and sale of available-for-sale investments 32,352,000 82,115,000
Net cash provided by (used in) investing activities (41,285,000) 39,307,000
Cash flows from financing activities:    
Dividends paid to stockholders 0 (19,091,000)
Repurchased Restricted Common Stock 25,000 0
Distributions to noncontrolling interests in operating subsidiary 1,358,000 0
Proceeds from exercises of stock options 242,000 938,000
Net cash used in financing activities (1,141,000) (18,153,000)
Increase (decrease) in cash and cash equivalents (19,207,000) 23,309,000
Cash and cash equivalents, beginning 135,223,000 134,466,000
Cash and cash equivalents, ending $ 116,016,000 $ 157,775,000